



Bayer-Tsinghua Collaboration

*2022 Call for Proposals for
Bayer Microfunding*



**Collaborate to Cure Hub China
Bayer Pharmaceuticals**

拜耳处方药中国合作创新中心

July 2022



RESTRICTED



Introduction

About Bayer Microfunding

To encourage research translation in drug discovery, Bayer will support Tsinghua in three **Microfunding** projects by an aggregate amount of up to 1.2 million CNY per year.

- // Each Microfunding project can be funded with up to a total of 400 kCNY for a maximum duration of two years
- // Microfunding projects will be research projects in Bayer's interested area, the projects will be solely conducted by Tsinghua investigators without involvement of Bayer. However, Bayer will try the best if any support is needed
- // The funding is to support Tsinghua Investigators to freely explore innovation translation, therefore, any project results deriving from a Microfunding project will solely be owned by Tsinghua

Who May Apply?

- // Eligible applicants need to be full-time employees of Tsinghua at the time of applying and receiving the fund
- // Working in the School of Life Sciences, School of Medicine, School of Pharmaceutical Sciences or Department of Chemistry, School of Information Science and Technology of Tsinghua
- // Independent of having a project with Bayer or not
- // **Must not** be healthcare professionals, or employed by a hospital due to international compliance requirements
- // Members of the Joint Steering Committee (JSC) may not apply for the fund
- // Having clear path of translating their research



Evaluation Process

- // The proposal will be evaluated based on the following considerations:
 - // Feasibility of translating your research to drug discovery
 - // Innovation and breakthrough potential in solving current unmet needs in diseases and drug discovery
 - // Research relevance to Bayer's areas of interest, including:
 - // Therapeutic areas in Oncology, Cardiovascular Diseases, Women's health, Ophthalmology, Hematology, Lung diseases, Kidney diseases;
 - // Disease mechanism understanding;
 - // Disruptive technologies/platforms that enable target identification/drug discovery;
 - // Novel therapeutic modalities, e.g. peptide binders, protein degraders, molecular glue, RNA therapeutics, cell and gene therapy;
 - // Novel delivery technologies for targeted tissues, new modalities, large biomolecules
- // The proposal provided will be evaluated by Bayer scientific experts and the Joint Steering Committee (JSC) from both Bayer and Tsinghua University
- // Decision Letter will be sent out in September 2022. Bayer Alliance Manager will contact you regarding the decision and discuss the next steps.



Obligation

// **Use of Microfunding:**

- // The Microfunding shall be used exclusively for the performance of the Microfunding projects
- // Microfunding cannot be used to fund equipment and infrastructure.

// **Recipients of Bayer Microfunding Shall:**

- // Provide a mid-term and final report to Bayer for the project progress
- // Acknowledge funding by Bayer in their talks and publications in related areas of interest



Submission Process

- // **Submit your proposal by Aug 20th 2022**
- // Please use the Application Form to submit an abstract of your research proposal or technology
- // Please indicate in the abstract :
 - // What unmet need your research addresses?
 - // What is the advantage/differentiation of your solution?
 - // IP situation
 - // Path forward for the translation of your research

// **Please note that only non-confidential information should be provided**

// **Submit your proposal to Bayer and Tsinghua Alliance Managers**

Min Wei, Ph.D. (未敏)

Yinghui Liu, Ph.D. (刘迎辉)

Collaborate to Cure Hub China
Bayer Pharmaceuticals

General Office of Institute of Biomedicine
Tsinghua University

Tel: +86 21 61593553

Tel: +86 10 62795305

Mobile: +86 15921237622

Mobile: +86 13164201518

E-mail: min.wei@bayer.com

E-mail: yhliu624@mail.tsinghua.edu.cn



Thank you!

